Nurix Therapeutics NRIX
Nurix Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$27.26+2.10%close on Oct. 28, 2026 · volume 2.0M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 15, 2026 | Gwenn Hansen Chief Scientific Officer | Sold 10b5-1 plan | 1,452 | $25.00 | $36,300 |
| Oct. 14, 2026 | Julia P. Gregory director | Sold | 22,583 | $23.40 | $528,528 |
| Oct. 2, 2026 | Christine Ring Chief Legal Officer | Sold 10b5-1 plan | 5,786 | $23.19 | $134,149 |
| Sept. 2, 2026 | Christine Ring Chief Legal Officer | Sold 10b5-1 plan | 5,787 | $25.76 $25.69-$26.64 | $149,072 |
| Sept. 1, 2026 | Gwenn Hansen Chief Scientific Officer | Sold 10b5-1 plan | 1,452 | $25.47 | $36,982 |
| Aug. 5, 2026 | Gwenn Hansen Chief Scientific Officer | Sold 10b5-1 plan | 4,356 | $25.00 | $108,900 |
| Aug. 4, 2026 | Gwenn Hansen Chief Scientific Officer | Sold 10b5-1 plan | 4,111 | $24.36 $23.87-$24.64 | $100,142 |
| Aug. 4, 2026 | Hans van Houte Chief Financial Officer | Sold 10b5-1 plan | 4,761 | $24.36 $23.89-$24.65 | $115,989 |
| Aug. 3, 2026 | Christine Ring Chief Legal Officer | Sold 10b5-1 plan | 16,589 | $23.05 | $382,358 |
| July 30, 2026 | Hans van Houte Chief Financial Officer | Sold | 2,845 | $23.38 | $66,524 |
| July 30, 2026 | Christine Ring Chief Legal Officer | Sold | 3,847 | $23.38 | $89,954 |
| July 30, 2026 | Gwenn Hansen Chief Scientific Officer | Sold | 3,847 | $23.38 | $89,954 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 21 →Results of operations and financial condition · Financial statements and exhibits